Huadong Medicine Group
Guided by the philosophy of “research-driven and patient-centered,” we are committed to becoming a leading international pharmaceutical brand powered by scientific and technological innovation.
Huadong Medicine Co., Ltd. is headquartered in Hangzhou, Zhejiang Province. Huadong Medicine has been repeatedly recognized among the “Top 50 Best Listed Companies in Asia-Pacific” by Forbes, ranked among the “Top 100 Most Valuable Listed Companies in China’s Main Board Market”, and has been included for many consecutive years in the Fortune China 500 list selected by Fortune China. It was also selected among the Top 50 Global Pharmaceutical Companies in 2025 by the U.S. magazine Pharmaceutical Executive. It has also been ranked among the Top 10 in the “China Top 100 Pharmaceutical Industrial Enterprises” for consecutive years. With a business presence spanning the entire pharmaceutical industry chain, Huadong Medicine operates across four business segments, including pharmaceutical manufacturing, pharmaceutical distribution, medical aesthetics, and industrial microbiology, and has grown into a large, comprehensive listed pharmaceutical company integrating pharmaceutical innovative R&D, manufacturing, and commercialization.
The company spans the entire pharmaceutical industry chain, focusing on four core segments: pharmaceutical development, pharmaceutical distribution, medical aesthetics, and microbiology. Today, it stands as a leading pharmaceutical enterprise specializing in innovative R&D, manufacturing, sales, and marketing.
Huadong Medicine has long been engaged in the R&D, manufacturing, and commercialization of specialty therapies, chronic disease medicines, and special-use medicines. With a complete, internationally oriented pharmaceutical manufacturing system, it has formed core product pipelines mainly covering chronic kidney disease, immunology, oncology, endocrinology, and digestive system diseases. Huadong Medicine has multiple frontline clinical products with strong market positions in China, and many products have obtained international registration certifications. It maintains R&D collaborations with a number of global innovation-driven R&D companies and has established China-market product strategic partnerships with multinational pharmaceutical companies, building the Huadong Medicine global R&D ecosystem. Through in-house development, external introductions, and project collaborations, it has focused its R&D on three core therapeutic areas: oncology, endocrinology, and autoimmune diseases. Leveraging its full industry chain to support biopharmaceutical industrialization, Huadong Medicine has invested in and built an internationally leading biomacromolecular drug R&D platform—the Biologics Innovation & Intelligent Manufacturing Center. The platform is dedicated to creating an end-to-end intelligent manufacturing base for biologics, focusing on high-barrier therapies such as monoclonal antibodies, bispecific antibodies, fusion proteins, and ADCs. Backed by an intelligent manufacturing ecosystem and globally compliant production capacity, it accelerates the efficient translation of First-in-Class molecules from the laboratory to global markets, completing a closed-loop innovation chain across the full biologics value chain and advancing breakthrough therapies to benefit patients worldwide.
Oncology
Huadong Medicine is committed to building a globally leading oncology innovation platform. The company has established an innovative oncology pipeline spanning targeted small-molecule therapies, ADCs, antibodies, and PROTACs, with more than 10 globally innovative drug candidates. In particular, in the field of oncology ADCs, Huadong Medicine has partnered with U.S.-based AbbVie to co-develop ELAHERE®, a first-in-class ADC for platinum-resistant ovarian cancer, which has been approved for marketing in China. The company has also invested in, established controlling interests in, and incubated multiple domestic biotechnology companies with leading technologies, building a comprehensive ADC technology ecosystem covering antibody discovery, linker technologies, and payload development. Germany’s Heidelberg Pharma operates a proprietary amanitin-based ADC technology platform and is currently the only company worldwide to have advanced amanitin-based ADC candidates into clinical development. Its HDP101 program for multiple myeloma has received Fast Track designation from the U.S. FDA, while HDP103, an amanitin-based ADC targeting PSMA for prostate cancer, is currently in the IND submission stage. Leveraging its unique global ADC R&D ecosystem, Huadong Medicine will continue to develop differentiated ADC therapies. The company has established a differentiated target portfolio and tiered pipeline covering targets such as FRα, ROR1, CDH17, MUC17, and EGFR/HER3, addressing indications including ovarian cancer, gastric cancer, pancreatic cancer, and hematologic malignancies. As one of the earliest companies in China to invest in the CAR-T field, Huadong Medicine has established strategic collaborations with leading domestic biopharmaceutical companies. Saikaize® (Zevorcabtagene Autoleucel Injection) has become one of the leading cell therapy products for multiple myeloma in China. In addition, an autologous CD19-targeted CAR-T candidate for diffuse large B-cell lymphoma, mantle cell lymphoma, and acute B-lymphoblastic leukemia received NDA acceptance in November 2024. Through its continued strategic investment in the CAR-T field, Huadong Medicine will further strengthen its competitiveness in the oncology market.
Endocrinology
Huadong Medicine has established a comprehensive portfolio of innovative drugs and differentiated generics covering the major clinical therapeutic targets for diabetes, with more than 20 commercialized and pipeline products. It is one of the leading companies in China’s diabetes market by market share. With a particular focus on the GLP-1 target, Huadong Medicine has built a comprehensive and differentiated product pipeline that integrates globally innovative therapies and biosimilars across multiple dosage forms, including oral and injectable formulations, as well as long-acting and multi-target therapies. Liraglutide Injection has obtained NMPA approval in China for both diabetes and obesity/weight-management indications, making it the first domestically developed liraglutide product approved for both indications in China. Its core products, HDM1002 and HDM1005, have both advanced into Phase III clinical trials for diabetes and weight-management indications. In addition, DR10624, a first-in-class long-acting triple agonist independently developed by the company’s controlled subsidiary, is currently undergoing multiple cutting-edge clinical studies for severe hypertriglyceridemia, metabolic dysfunction-associated steatotic liver disease (MASLD), and metabolic dysfunction-associated steatohepatitis (MASH). Its Phase II clinical study in severe hypertriglyceridemia was selected for presentation as an opening-session breakthrough study at the main scientific session of the 2025 American Heart Association (AHA) Scientific Sessions. Recognized as a pioneering clinical trial in cardiometabolic disease therapeutics, the study attracted significant attention and positive recognition from leading experts in the field, demonstrating its strong potential to become a first-in-class therapy in lipid metabolism and related metabolic diseases.
Autoimmunity
Huadong Medicine has become one of the pharmaceutical companies with the most comprehensive autoimmune disease portfolios in China. Its pipeline and marketed products cover indications including transplant immunology, psoriasis, atopic dermatitis, rheumatoid arthritis, seborrheic dermatitis, ankylosing spondylitis, prurigo nodularis, and vitiligo. At the same time, the company has actively expanded into topical formulations by establishing a dedicated topical formulation R&D platform covering a broad range of therapeutic indications. It has built fully integrated capabilities spanning the entire value chain, from R&D and regulatory registration to manufacturing and commercialization. Huadong Medicine now has a portfolio of 10 topical formulation products that are either under development or already commercialized. Notably, through strategic partnerships, the company has introduced two global first-in-class products: Wynzora® Cream, the world’s first and only once-daily fixed-dose combination calcipotriene and betamethasone dipropionate for the treatment of plaque psoriasis; and ZORYVE® Cream, the world’s first and only topical PDE4 inhibitor approved for the treatment of plaque psoriasis, including intertriginous psoriasis.
As a leading regional pharmaceutical distributor, Huadong Medicine has ranked among China’s top 10 pharmaceutical wholesalers for many consecutive years. Its business covers three major sectors: pharmaceuticals, medical devices, and Chinese medicinal materials and decoction pieces. Underpinned by an intelligent logistics network consisting of three core hubs in Hangzhou, Jinhua, and Wenzhou, as well as 13 logistics and warehousing facilities with a total storage area exceeding 190,000 square meters, the company bolsters its competitiveness edge through specialized logistics capabilities covering cold-chain products, specialty pharmaceuticals, and vaccines. The pharmaceutical sector enjoys comprehensive advantages through a full product portfolio, omnichannel coverage, integrated in-hospital and out-of-hospital services, and coordinated distribution and agency operations. To date, the company has established business partnerships with more than 95% of the world’s top 50 pharmaceutical companies and China’s top 100 pharmaceutical enterprises. The medical device sector leverages large-scale distribution capabilities to expand specialized agency services. The Chinese medicinal materials, ginseng & deer antler products, and decoction pieces sector encompasses the entire industrial chain, including cultivation at source, decoction-piece processing, automated decoction services, and the marketing of proprietary branded products.
Centered on its Full-Spectrum Health Aesthetics Strategy and driven by technology and innovation, the company has built a comprehensive full-spectrum health aesthetics portfolio comprising more than 50 international high-end medical aesthetics products, including injectables, photoelectric devices/energy-based devices (EBDs), ranking among industry leaders in both product breadth and coverage. Ellansé® is the first imported regenerative dermal filler approved in China. Lanluma® is the world’s only regenerative aesthetic injectable approved for body contouring and was awarded the “Best Body Filler Injection Award” at the 2023 Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco. KIO015 and KIO021 are first-in-class non-animal-derived chitosan aesthetic fillers featuring the world’s only high-purity, natural, medical-grade, non-animal-derived chitosan extracted from edible fungi. Recombinant Botulinum Toxin Type A, Ruituoxin®, received marketing approval in China in March 2026. The company operates global innovation and R&D centers as well as manufacturing bases across China, the United Kingdom, France, the Netherlands, Switzerland, Belgium, Spain, Bulgaria, and Israel. It has also established mature sales and marketing networks in North America, the EU market, Brazil, Mexico, the United Arab Emirates, Hong Kong SAR of China, and South Korea. Supported by a robust global operating platform, its commercial capabilities extend to more than 80 countries and regions worldwide.
Huadong Medicine has a strong industrial foundation and robust industrialization and commercialization capabilities in the field of industrial microbiology. It has successfully developed and manufactured a variety of microbial pharmaceuticals, established key technology platforms for the R&D and production of microbial products, and achieved industry-leading scale and technical capabilities in microbial fermentation products. The company focuses on two strategic directions: the application of synthetic biology technologies and innovation in biopharmaceuticals, with four core business sectors comprising xRNA, specialty APIs & intermediates, health and wellness & biomaterials, and animal health. In the animal health sector, the marketing registration application for Preropetide Injection, a Class 1 new veterinary drug in China independently developed by the company, has been accepted. The product is expected to become the world’s first long-acting GLP-1/GIP dual-target weight-management therapy for obese cats.
In industrial microbiology, Huadong Medicine has established an R&D cluster centered on the Synthetic Biology R&D Platform, the Industrial Microbiology R&D Platform, and the Synthetic Chemistry R&D Platform. It possesses full-chain microbial engineering capabilities and operates a large-scale single-unit fermentation workshop in Zhejiang Province. Its microbial pharmaceutical manufacturing capacity ranks among the industry leaders. Huadong Medicine has established an integrated R&D and manufacturing system covering the entire lifecycle of microbial pharmaceuticals and has built a cross-disciplinary R&D platform together with an industrialization support network.